The MDR1 gene product, P-glycoprotein, mediates the transport of the cardiac glycoside, digoxin

Biochem Biophys Res Commun. 1992 Nov 30;189(1):551-7. doi: 10.1016/0006-291x(92)91593-f.


Digoxin, a widely used cardiac glycoside with a low therapeutic index, is known to interact with a large and diverse group of co-administered drugs, frequently leading to toxic accumulation of the glycoside. Establishing the mechanism(s) of these interactions, therefore, has potential clinical significance. The present studies implicate P-glycoprotein, the MDR1 gene product overexpressed in multidrug resistant cells, as the apical membrane protein responsible for the renal secretion of digoxin and provide an explanation for the occurrence of digoxin toxicity in the presence of certain co-administered medications. Since digoxin is considered a prototype for endogenous digitalis-like glycosides, the results also allow for speculation that endogenous digitalis-like glycosides may be the natural substrates for P-gp.

Publication types

  • Comparative Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • ATP Binding Cassette Transporter, Subfamily B, Member 1
  • Animals
  • Biological Transport / drug effects
  • CHO Cells
  • Colchicine / pharmacology*
  • Cricetinae
  • Cyclosporine / pharmacology
  • Digoxin / metabolism*
  • Dose-Response Relationship, Drug
  • Drug Resistance / genetics*
  • Kinetics
  • Membrane Glycoproteins / genetics
  • Membrane Glycoproteins / metabolism*
  • Quinidine / pharmacology
  • Verapamil / pharmacology
  • Vinblastine / metabolism*


  • ATP Binding Cassette Transporter, Subfamily B, Member 1
  • Membrane Glycoproteins
  • Vinblastine
  • Digoxin
  • Cyclosporine
  • Verapamil
  • Quinidine
  • Colchicine